Skip to main content
  • Letter to the Editor
  • Open access
  • Published:

Association between radiation pneumonitis and tumor response in patients with NSCLC treated with chemoradiation

Abstract

Dang and colleagues recently reported in the journal that tumor response to definitive chemoradiation, as assessed using the RECIST criteria, and the risk of radiation pneumonitis were positively correlated in patients with non-small cell lung cancer (NSCLC). We had previously reported similar findings in a study that used positron tomography both to measure tumor response and to assess normal tissue toxicity in patients treated with chemoradiation for NSCLC. Taken together these reports suggest that radiosensitivity of normal tissues and tumors may be strongly linked in a proportion of patients with lung cancer.

Correspondence

We read the recent article published in the journal by Dang and colleagues with interest [1]. These authors reported that tumor response to definitive chemoradiation, as assessed using the Response Evaluation Criteria In Solid Tumors (RECIST) criteria, and the risk of radiation pneumonitis were positively correlated in patients with non-small cell lung cancer (NSCLC). This is not the first time that such an association between tumor response and radiation-induced pulmonary toxicity has been reported in patients with NSCLC. In 2004, our group published the results of a study that investigated the relationship between positron emission tomography (PET)-detected inflammatory changes in irradiated normal tissues and clinical response at tumor sites in 73 patients treated with radical radiotherapy or chemoradiotherapy for NSCLC [2]. Radiation-induced inflammatory change was scored for normal tissues within the radiation treatment volume using a 0–3 grading scale. Metabolic tumor response was assessed using standardized visual metabolic response criteria. Increased fluorodeoxyglucose (FDG) uptake in normal tissues (radiotoxicity) was associated with a greater likelihood of complete or partial tumor response as assessed by both PET (p =0.0044) and computed tomography (p = 0.029). In a subsequent publication in 2011 we reported that PET-detected radiotoxicity and radiation pneumonitis were strongly associated [3]. FDG uptake in pulmonary tissues therefore appeared to reflect the inflammatory changes induced by radiation pneumonitis. Taken together, our results and the results reported by Dang and colleagues suggest that the intrinsic radiosensitivity of thoracic normal tissues and tumor responsiveness to chemoradiation may be related in at least a proportion of patients with NSCLC. These observations could potentially have useful implications for patient management. If the molecular basis of this phenomenon could be understood, it may be possible in future to estimate the likely radiosensitivity of both the tumor and the normal tissues of individual patients with NSCLC and use this information to better individualize therapy.

Abbreviations

FDG:

Fluorodeoxyglucose

NSCLC:

Non-small cell lung cancer

PET:

Positron emission tomography

RECIST:

Response Evaluation Criteria In Solid Tumors.

References

  1. Dang J, Li G, Zang S, Zhang S, Yao L: Risk and predictors for early radiation pneumonitis in patients with stage III non-small cell lung cancer treated with concurrent or sequential chemoradiotherapy. Radiat Oncol 2014,9(1):172. 10.1186/1748-717X-9-172

    Article  PubMed Central  PubMed  Google Scholar 

  2. Hicks RJ, Mac Manus MP, Matthews JP, Hogg A, Binns DS, Rischin D, Ball DL, Peters LJ: Early FDG-PET imaging after radical radiotherapy for non-small-cell lung cancer: inflammatory changes in normal tissues correlate with tumor response and do not compound therapeutic response evaluation. Int J Radiat Oncol Biol Phys 2004,60(2):412-418. 10.1016/j.ijrobp.2004.03.036

    Article  PubMed  Google Scholar 

  3. Mac Manus MP, Ding Z, Hogg A, Herschtal A, Binns D, Ball DL, Hicks RJ: Association between pulmonary uptake of fluorodeoxyglucose detected by positron emission tomography scanning after radiation therapy for non-small-cell lung cancer and radiation pneumonitis. Int J Radiat Oncol Biol Phys 2011,80(5):1365-1371. 10.1016/j.ijrobp.2010.04.021

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Michael P MacManus.

Additional information

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

All authors contributed equally and are co-investigators on the study referred to in the letter. All authors read and approved the final manuscript.

Rights and permissions

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

MacManus, M.P., Ball, D. & Hicks, R.J. Association between radiation pneumonitis and tumor response in patients with NSCLC treated with chemoradiation. Radiat Oncol 9, 217 (2014). https://doi.org/10.1186/1748-717X-9-217

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/1748-717X-9-217

Keywords